Physician profile
Michael Shaughnessy
NPI 1699728402
$3,859.36
in general payments reported to CMS, 2019-2025
24 companies · $976 in 2025
The $976 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $202 · 2021: $449 · 2022: $523 · 2023: $467 · 2024: $866 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,012.94 | 2019-2025 | Clareon, Lensx, Unity |
| Abbvie INC. | $524.33 | 2022-2025 | Durysta |
| Allergan, INC. | $354.17 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $320.31 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $279.37 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $249.47 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $233.02 | 2020-2023 | Acthar |
| Dompe US, INC. | $199.99 | 2019-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $137.70 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $92.92 | 2024-2025 | Xdemvy |
| Amgen INC. | $85.31 | 2024-2025 | Tepezza |
| New World Medical,INC. | $59.77 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Ivantis, INC | $39.03 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $38.95 | 2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.35 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $29.82 | 2024 | Triesence, Iheezo |
| Shire North American Group INC | $29.44 | 2019 | |
| Kala Pharmaceuticals, INC. | $28.30 | 2019 | |
| Glaukos Corporation | $25.43 | 2025 | Idosetr, Istent Infinite |
| Omeros Corporation | $23.01 | 2019 | |
| Eyevance Pharmaceuticals LLC | $22.04 | 2023 | Flarex |
| Tearlab Corp | $16.50 | 2022 | |
| Spark Therapeutics, INC. | $16.20 | 2022 | |
| Biotissue Holdings INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shaughnessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.